Identification
NameRanpirnase
Accession NumberDB04950
TypeBiotech
GroupsInvestigational
Description

Ranpirnase is a ribonuclease enzyme found in Rana pipiens oocytes. It is being studied in the treatment of cancer. It is manufactured by Alfacell Corporation. It is the first ribonuclease to enter cancer clinical trials.

Protein structureNo structure small
Related Articles
Protein chemical formulaNot Available
Protein average weightNot Available
SequencesNot Available
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
OnconaseNot Available
Brand mixturesNot Available
Categories
UNIIZE15FIT23E
CAS number196488-72-9
Pharmacology
Indication

For the treatment of various forms of cancer.

Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action

Ranpirnase controls tumour growth by degrading RNA within cancer cells, resulting in inhibition of protein synthesis and arresting mitosis in G(1)phase.

TargetKindPharmacological actionActionsOrganismUniProt ID
DNANucleotideunknownNot AvailableHumannot applicabledetails
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Ranpirnase.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Ranpirnase.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ranpirnase.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Ranpirnase.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Ranpirnase.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Ranpirnase.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Ranpirnase.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ranpirnase.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Ranpirnase.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Ranpirnase.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ranpirnase.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Ranpirnase.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Vogelzang NJ, Aklilu M, Stadler WM, Dumas MC, Mikulski SM: A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer. Invest New Drugs. 2001;19(3):255-60. [PubMed:11561684 ]
  2. Pavlakis N, Vogelzang NJ: Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma. Expert Opin Biol Ther. 2006 Apr;6(4):391-9. [PubMed:16548765 ]
  3. Authors unspecified: Ranpirnase: amphibian ribonuclease A, P-30 protein-alfacell. Drugs R D. 2007;8(2):120-4. [PubMed:17324010 ]
  4. Lee I, Kalota A, Gewirtz AM, Shogen K: Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice. Anticancer Res. 2007 Jan-Feb;27(1A):299-307. [PubMed:17352247 ]
  5. Lee I, Kim DH, Sunar U, Magnitsky S, Shogen K: The therapeutic mechanisms of ranpirnase-induced enhancement of radiation response on A549 human lung cancer. In Vivo. 2007 Sep-Oct;21(5):721-8. [PubMed:18019404 ]
  6. Suhasini AN, Sirdeshmukh R: Transfer RNA cleavages by onconase reveal unusual cleavage sites. J Biol Chem. 2006 May 5;281(18):12201-9. Epub 2006 Feb 23. [PubMed:16497678 ]
  7. Link [Link]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2CompletedTreatmentCondylomata Acuminata / Papillomavirus Infections / Sexually Transmitted Disease (STD)1
2WithdrawnTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
3Unknown StatusTreatmentMesothelioma, Malignant1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
unknown
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Authors unspecified: Ranpirnase: amphibian ribonuclease A, P-30 protein-alfacell. Drugs R D. 2007;8(2):120-4. [PubMed:17324010 ]
Drug created on October 21, 2007 16:23 / Updated on August 17, 2016 12:24